Quick Answer
VACCINEX, INC. reported Stockholders Equity of $7.41 million for the year ending 2021.
- VACCINEX, INC. showed an increase of +127.9% in Stockholders Equity from 2020 to 2021.
- This data is from VACCINEX, INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2022.
- XBRL data for this metric is available from 2017 to 2021 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$139.83 million | Q3 2018: -$218.0 thousand | Q1 2019: -$17.63 million | Q2 2019: -$26.34 million | Q3 2019: -$20.05 million | Q1 2020: -$25.70 million | Q2 2020: -$29.54 million | Q3 2020: -$20.20 million | Q1 2021: $818.0 thousand | Q2 2021: $16.94 million | Q3 2021: $11.89 million.
- Over the full 5 years of available data (2017 to 2021), VACCINEX, INC.'s Stockholders Equity has grown by 105.9%.
- Historical annual values: Fiscal year 2021: $7.41 million | Fiscal year 2020: -$26.58 million | Fiscal year 2019: -$26.24 million | Fiscal year 2018: -$8.62 million | Fiscal year 2017: -$125.45 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: